ADICET BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.47 USD | -9.82% |
|
+1.38% | -22.22% |
Presenter SpeechChen Schor (Executives)Good morning, everybody, and thank you for joining us t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Calendar
2024-05-14
- Citizens JMP Life Sciences Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.47
USD
Average target price
9.6
USD
Spread / Average Target
+553.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.22% | 121M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- ACET Stock
- News Adicet Bio, Inc.
- Transcript : resTORbio, Inc. - Special Call